Allianz Asset Management GmbH Has $96.67 Million Holdings in Becton Dickinson and Co (BDX)

Allianz Asset Management GmbH boosted its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 3.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 370,390 shares of the medical instruments supplier’s stock after acquiring an additional 12,101 shares during the quarter. Allianz Asset Management GmbH owned about 0.14% of Becton Dickinson and worth $96,671,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of BDX. Cornerstone Wealth Management LLC acquired a new stake in shares of Becton Dickinson and in the 2nd quarter valued at $812,000. Commonwealth Equity Services LLC raised its holdings in shares of Becton Dickinson and by 8.2% in the second quarter. Commonwealth Equity Services LLC now owns 61,021 shares of the medical instruments supplier’s stock valued at $14,618,000 after buying an additional 4,648 shares during the last quarter. CWM LLC raised its holdings in shares of Becton Dickinson and by 390.6% in the second quarter. CWM LLC now owns 785 shares of the medical instruments supplier’s stock valued at $188,000 after buying an additional 625 shares during the last quarter. Bartlett & Co. LLC raised its holdings in shares of Becton Dickinson and by 2,900.0% in the second quarter. Bartlett & Co. LLC now owns 450 shares of the medical instruments supplier’s stock valued at $108,000 after buying an additional 435 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. raised its holdings in shares of Becton Dickinson and by 103.7% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 58,135 shares of the medical instruments supplier’s stock valued at $13,927,000 after buying an additional 29,600 shares during the last quarter. 86.25% of the stock is currently owned by institutional investors.

A number of research analysts recently issued reports on BDX shares. KeyCorp lifted their price target on Becton Dickinson and from $264.00 to $273.00 and gave the company an “overweight” rating in a report on Thursday, November 8th. Wells Fargo & Co lifted their price target on Becton Dickinson and from $275.00 to $290.00 and gave the company an “outperform” rating in a report on Thursday, September 6th. They noted that the move was a valuation call. Citigroup cut their price target on Becton Dickinson and from $289.00 to $279.00 and set a “buy” rating for the company in a report on Tuesday, November 13th. Morgan Stanley lifted their price target on Becton Dickinson and from $250.00 to $280.00 and gave the company an “equal weight” rating in a report on Thursday, October 4th. Finally, UBS Group started coverage on Becton Dickinson and in a report on Tuesday. They issued a “neutral” rating and a $260.00 price target for the company. Six investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $254.20.

In other Becton Dickinson and news, SVP Charles R. Bodner sold 2,080 shares of the business’s stock in a transaction dated Friday, November 16th. The stock was sold at an average price of $245.83, for a total transaction of $511,326.40. Following the completion of the sale, the senior vice president now directly owns 4,497 shares of the company’s stock, valued at approximately $1,105,497.51. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Vincent A. Forlenza sold 16,866 shares of the business’s stock in a transaction dated Tuesday, November 13th. The stock was sold at an average price of $237.61, for a total value of $4,007,530.26. The disclosure for this sale can be found here. Insiders have sold a total of 75,908 shares of company stock valued at $18,085,616 over the last three months. Company insiders own 1.00% of the company’s stock.

Shares of NYSE:BDX opened at $250.10 on Friday. The stock has a market cap of $65.32 billion, a price-to-earnings ratio of 22.72, a PEG ratio of 1.68 and a beta of 1.19. Becton Dickinson and Co has a 1-year low of $209.91 and a 1-year high of $265.87. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.23 and a quick ratio of 0.81.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $2.93. The firm had revenue of $4.40 billion during the quarter, compared to analysts’ expectations of $4.36 billion. Becton Dickinson and had a return on equity of 13.84% and a net margin of 1.47%. The company’s quarterly revenue was up 39.0% compared to the same quarter last year. During the same period in the previous year, the business posted $2.40 EPS. As a group, sell-side analysts expect that Becton Dickinson and Co will post 12.1 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 31st. Shareholders of record on Monday, December 10th will be issued a dividend of $0.77 per share. This is a boost from Becton Dickinson and’s previous quarterly dividend of $0.75. This represents a $3.08 annualized dividend and a yield of 1.23%. The ex-dividend date is Friday, December 7th. Becton Dickinson and’s payout ratio is currently 27.25%.

COPYRIGHT VIOLATION NOTICE: This report was posted by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.americanbankingnews.com/2018/11/30/allianz-asset-management-gmbh-has-96-67-million-holdings-in-becton-dickinson-and-co-bdx.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Recommended Story: What are Institutional Investors?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply